|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WDR18 |
Gene summary for WDR18 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WDR18 | Gene ID | 57418 |
| Gene name | WD repeat domain 18 | |
| Gene Alias | Ipi3 | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9BV38 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57418 | WDR18 | P79T-E | Human | Esophagus | ESCC | 2.94e-27 | 6.18e-01 | 0.1154 |
| 57418 | WDR18 | P80T-E | Human | Esophagus | ESCC | 1.24e-61 | 1.61e+00 | 0.155 |
| 57418 | WDR18 | P82T-E | Human | Esophagus | ESCC | 1.48e-23 | 1.07e+00 | 0.1072 |
| 57418 | WDR18 | P83T-E | Human | Esophagus | ESCC | 3.02e-74 | 1.82e+00 | 0.1738 |
| 57418 | WDR18 | P84T-E | Human | Esophagus | ESCC | 6.67e-10 | 5.50e-01 | 0.0933 |
| 57418 | WDR18 | P89T-E | Human | Esophagus | ESCC | 6.12e-28 | 1.72e+00 | 0.1752 |
| 57418 | WDR18 | P91T-E | Human | Esophagus | ESCC | 3.04e-18 | 1.78e+00 | 0.1828 |
| 57418 | WDR18 | P94T-E | Human | Esophagus | ESCC | 1.83e-02 | 6.00e-01 | 0.0879 |
| 57418 | WDR18 | P104T-E | Human | Esophagus | ESCC | 1.67e-03 | 4.62e-01 | 0.0931 |
| 57418 | WDR18 | P107T-E | Human | Esophagus | ESCC | 9.25e-74 | 1.62e+00 | 0.171 |
| 57418 | WDR18 | P126T-E | Human | Esophagus | ESCC | 7.02e-12 | 1.13e+00 | 0.1125 |
| 57418 | WDR18 | P127T-E | Human | Esophagus | ESCC | 6.93e-19 | 3.33e-01 | 0.0826 |
| 57418 | WDR18 | P128T-E | Human | Esophagus | ESCC | 4.71e-54 | 1.52e+00 | 0.1241 |
| 57418 | WDR18 | P130T-E | Human | Esophagus | ESCC | 3.13e-62 | 1.38e+00 | 0.1676 |
| 57418 | WDR18 | HCC1_Meng | Human | Liver | HCC | 1.93e-56 | 7.45e-02 | 0.0246 |
| 57418 | WDR18 | HCC2_Meng | Human | Liver | HCC | 3.02e-19 | 6.37e-02 | 0.0107 |
| 57418 | WDR18 | cirrhotic1 | Human | Liver | Cirrhotic | 1.29e-10 | 2.68e-01 | 0.0202 |
| 57418 | WDR18 | cirrhotic2 | Human | Liver | Cirrhotic | 3.06e-03 | 1.19e-01 | 0.0201 |
| 57418 | WDR18 | cirrhotic3 | Human | Liver | Cirrhotic | 2.02e-03 | 1.45e-01 | 0.0215 |
| 57418 | WDR18 | HCC2 | Human | Liver | HCC | 2.77e-02 | 2.68e+00 | 0.5341 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613 | Colorectum | AD | ribonucleoprotein complex biogenesis | 151/3918 | 463/18723 | 1.96e-09 | 1.39e-07 | 151 |
| GO:0051052 | Colorectum | AD | regulation of DNA metabolic process | 116/3918 | 359/18723 | 2.47e-07 | 1.00e-05 | 116 |
| GO:0042254 | Colorectum | AD | ribosome biogenesis | 84/3918 | 299/18723 | 1.82e-03 | 1.50e-02 | 84 |
| GO:00226131 | Colorectum | SER | ribonucleoprotein complex biogenesis | 112/2897 | 463/18723 | 5.01e-07 | 2.48e-05 | 112 |
| GO:00510521 | Colorectum | SER | regulation of DNA metabolic process | 83/2897 | 359/18723 | 8.03e-05 | 1.77e-03 | 83 |
| GO:00422541 | Colorectum | SER | ribosome biogenesis | 66/2897 | 299/18723 | 1.48e-03 | 1.60e-02 | 66 |
| GO:00226132 | Colorectum | MSS | ribonucleoprotein complex biogenesis | 144/3467 | 463/18723 | 2.76e-11 | 3.67e-09 | 144 |
| GO:00510522 | Colorectum | MSS | regulation of DNA metabolic process | 108/3467 | 359/18723 | 5.86e-08 | 3.10e-06 | 108 |
| GO:00422542 | Colorectum | MSS | ribosome biogenesis | 79/3467 | 299/18723 | 4.32e-04 | 5.23e-03 | 79 |
| GO:0006364 | Colorectum | MSS | rRNA processing | 58/3467 | 225/18723 | 4.17e-03 | 3.03e-02 | 58 |
| GO:0016072 | Colorectum | MSS | rRNA metabolic process | 60/3467 | 236/18723 | 5.01e-03 | 3.46e-02 | 60 |
| GO:00226133 | Colorectum | MSI-H | ribonucleoprotein complex biogenesis | 95/1319 | 463/18723 | 1.04e-21 | 8.32e-19 | 95 |
| GO:00422543 | Colorectum | MSI-H | ribosome biogenesis | 54/1319 | 299/18723 | 1.27e-10 | 2.07e-08 | 54 |
| GO:00063641 | Colorectum | MSI-H | rRNA processing | 39/1319 | 225/18723 | 1.45e-07 | 1.32e-05 | 39 |
| GO:00160721 | Colorectum | MSI-H | rRNA metabolic process | 39/1319 | 236/18723 | 5.20e-07 | 3.91e-05 | 39 |
| GO:00510523 | Colorectum | MSI-H | regulation of DNA metabolic process | 45/1319 | 359/18723 | 1.20e-04 | 3.56e-03 | 45 |
| GO:0034470 | Colorectum | MSI-H | ncRNA processing | 48/1319 | 395/18723 | 1.54e-04 | 4.47e-03 | 48 |
| GO:0034660 | Colorectum | MSI-H | ncRNA metabolic process | 53/1319 | 485/18723 | 9.66e-04 | 1.68e-02 | 53 |
| GO:0006260 | Colorectum | MSI-H | DNA replication | 31/1319 | 260/18723 | 2.83e-03 | 3.63e-02 | 31 |
| GO:002261327 | Esophagus | HGIN | ribonucleoprotein complex biogenesis | 158/2587 | 463/18723 | 2.61e-29 | 5.23e-26 | 158 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WDR18 | SNV | Missense_Mutation | novel | c.146N>A | p.Gly49Asp | p.G49D | Q9BV38 | protein_coding | tolerated(0.05) | possibly_damaging(0.814) | TCGA-JL-A3YW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| WDR18 | SNV | Missense_Mutation | rs778985723 | c.827C>T | p.Ser276Leu | p.S276L | Q9BV38 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| WDR18 | insertion | Frame_Shift_Ins | novel | c.631_632insG | p.Ser211CysfsTer5 | p.S211Cfs*5 | Q9BV38 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
| WDR18 | insertion | Frame_Shift_Ins | novel | c.632_633insA | p.Val212ArgfsTer4 | p.V212Rfs*4 | Q9BV38 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
| WDR18 | SNV | Missense_Mutation | c.697N>A | p.Gly233Arg | p.G233R | Q9BV38 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| WDR18 | deletion | Frame_Shift_Del | novel | c.619delG | p.Glu207SerfsTer15 | p.E207Sfs*15 | Q9BV38 | protein_coding | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| WDR18 | SNV | Missense_Mutation | rs376924638 | c.1195C>T | p.Arg399Cys | p.R399C | Q9BV38 | protein_coding | deleterious(0.03) | possibly_damaging(0.828) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WDR18 | SNV | Missense_Mutation | rs376924638 | c.1195C>T | p.Arg399Cys | p.R399C | Q9BV38 | protein_coding | deleterious(0.03) | possibly_damaging(0.828) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WDR18 | SNV | Missense_Mutation | novel | c.26N>A | p.Val9Glu | p.V9E | Q9BV38 | protein_coding | deleterious(0) | possibly_damaging(0.593) | TCGA-AP-A1DO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| WDR18 | SNV | Missense_Mutation | rs775172395 | c.868N>A | p.Asp290Asn | p.D290N | Q9BV38 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |